Geneva, July 20 -- International Clinical Trials Registry received information related to the study (ACTRN12626000830392) titled 'sTereOtactic Radiotherapy aNd Androgen suppression for De novo Oligometastatic prostate cancer' on July 10.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Primary Sponsor: Alfred Hospital
Condition:
De novo metastatic prostate cancer
De novo metastatic prostate cancer
Cancer - Prostate
Intervention:
Patients will receive stereotactic ablative body radiotherapy (SABR) to the prostate and metastatic sites delivered in two fractions, one fraction per week. Each SABR session will take approximately 30 minutes, This study will aim to deliver 2-fraction SABR 24 Gy...